Sodium thiosulfate - Fennec Pharmaceuticals
Alternative Names: PEDMARK; PEDMARQSI; Sodium hyposulfite; STS - FennecLatest Information Update: 28 Aug 2025
At a glance
- Originator Oregon Health & Science University
- Developer Fennec Pharmaceuticals
- Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates; Vasodilators
- Mechanism of Action Antioxidants; Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Sensorineural hearing loss
Most Recent Events
- 14 Aug 2025 Fennec Pharmaceuticals announces intention to submit NDA to Japan PMDA for Sensorineural hearing loss
- 14 Aug 2025 Fennec Pharmaceuticals plans to launch Sodium thiosulfate (PEDMARQSI®) for Sensorineural hearing loss in additional EU countries
- 31 May 2025 Fennec Pharmaceuticals has patent protection for pharmaceutical composition comprising sodium thiosulfate in USA